Clinical Trial Update: Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients [Phase 2]

View source ↗

Summary

Phase 2 study evaluating azacitidine with pembrolizumab in relapsed/refractory AML and newly diagnosed older patients; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2023-03-01